Shaping the standard of care in ovarian cancer management: A review of Gynecologic Oncology Group (GOG)/NRG oncology clinical trials of the past twenty years


      • The GOG/NRG Oncology has led the evolution of ovarian cancer treatment through clinical trials.
      • The GOG/NRG Oncology has adapted to the changing landscape of cancer therapy.
      • Active GOG/NRG Oncology trials may radically change the paradigm of how we treat ovarian cancer.


      The Gynecologic Oncology Group (GOG), now part of the NRG Oncology network since the re-alignment of the National Clinical Trials Network in 2014, has played a fundamental role in creating the standard of care for women with ovarian cancer. GOG/NRG Oncology has had a series of achievements that have contributed to how we treat this disease; the approval of bevacizumab in frontline therapy, defining the role of intraperitoneal chemotherapy, optimal chemotherapy for early stage disease and the role of surgery in primary and recurrent disease management. Going forward, GOG/NRG Oncology is positioned to meet the ever changing knowledge that we have about the molecular background of this disease and the expanding repertoire of drugs/interventions in development.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics 2018.
        CA Cancer J. Clin. 2018; 68: 7-30
        • Cancer Genome Atlas Research Network
        Integrated genomic analysis of ovarian cancer.
        Nature. 2011; 474: 609-615
        • NCI Clinical Announcement
        Intraperitoneal Chemotherapy in Ovarian Cancer.
      1. R.A. Burger, M.F. Brady, M.A. Bookman, G.F. Fleming, B.J. Monk, R.S. Mannel, et al., Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med.. 365 (26) (2011) 2473–83.

        • Schorge J.S.
        • Bregar A.J.
        • Durfee J.
        • Berkowitz R.
        Meigs to modern times: the evolution of debulking surgery in advanced ovarian cancer.
        Gynecol. Oncol. 2018; 149: 447-454
      2. M.M. Hreshchyshyn, R.C. Park, J.A. Blessing, H.J. Norris, D. Levy, L.D. Lagasse, et al., The role of adjuvant chemotherapy in stage I ovarian cancer. Am. J. Obstet. Gynecol.. 138 (2) (1980) 139–145.

      3. R.C. Young, L.A. Walton, S.S. Ellenberg, H.D. Homesley, G.D. Wilbanks, D.G. Decker, et al., Adjuvant therapy in stage I and stage II epithelial ovarian cancer: results of two prospective randomized trials. NEJM. 322 (15) (1990) 1021–1027.

      4. R.C. Young, M.F. Brady, R.K. Nieberg, H.J. Long, A.R. Mayer, S.S. Lentz, et al., Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal. 32P or intravenous cyclophospamide and cisplatin—a gynecologic oncology group study. J Clin Onc. 21 (23) (2003) 4350–55.

      5. J Bell, M.F. Brady, R.C. Young, J Lage, J.L. Walker, K.Y. Look, et al., Randomized phase III trial of carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a gynecologic oncology group study. Gynecol. Oncol.. 102 (3) (2006) 432–9.

      6. J.K. Chan, C. Tian, G.F. Fleming, B.J. Monk, T.J. Herzog, D.S. Kapp, et al., The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a gynecologic oncology group study. Gynecol. Oncol.. 116 (3) (2010) 301–306.

      7. R.S. Mannel, M.F. Brady, E.C. Kohn, P. Hanjani, M. Hiura, R. Lee, et al., A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a gynecologic oncology group study. Gynecol. Oncol.. 122 (1) (2011) 89–94.

        • Hoskins W.J.
        • Bundy B.N.
        • Thigpen J.T.
        • Omura G.A.
        The influence of cytoreductive surgery on recurrence-free interval and survival in small volume stage III epithelial ovarian cancer: a GOG study.
        Gynecol. Oncol. 1992; 47: 159-166
      8. W.J. Hoskins, W.P. McGuire, M.F. Brady, H.D. Homesley, W.T. Creasman, M. Berman, et al., The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol.. 170 (4) (1994) 974–980.

        • Thigpen J.T.
        • Blessing J.A.
        • Ball H.
        • Hummel S.J.
        • Barrett R.J.
        Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a gynecologic oncology group study.
        J. Clin. Oncol. 1994; 12: 1748-1753
      9. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, K.Y. Loook, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. New Engl J Med. 334 (1996) 1–6.

        • Muggia F.M.
        • Braly P.S.
        • Brady M.F.
        • Sutton G.
        • Niemann T.H.
        • Lentz S.L.
        A phase III randomized study of cisplatin (NSC #119875) versus taxol (NSC #125973) versus taxol and cisplatin in patients with suboptimal stage III and IV epithelial ovarian carcinoma.
        J. Clin. Oncol. 2000; 18: 106-115
      10. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, R.A. Burger, et al., Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study (158). J. Clin. Oncol..21 (17) (2003) 3194–200.

      11. M.A. Bookman, M.F. Brady, W.P McGuire, P.G. Harper, D.S. Alberts, M. Friedlander, et al., Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup. J. Clin. Oncol.. 27 (9) (2009) 1419–25.

      12. T.J. Perren, A.M. Swart, J. Pfisterer, J.A. Ledermann, E. Pujade-Lauraine, G. Kristensen, et al., A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med.. 366 (3) (2011) 2484–96.

        • U.S. Food and Drug Administration
        FDA Approves Bevacizumab in Combination with Chemotherapy for Ovarian Cancer.
        June 13, 2018
      13. N. Katsumata, M. Yasuda, F. Takahashi, S. Isonishi, T. Jobo, D. Aoki, et al., Dose-dense paclitaxel once a week in combination with carboplatin every three weeks for advanced ovarian cancer: a phase 3, open-label randomized controlled trial. Lancet. 374 (9698) (2009) 1331–8.

      14. J.K. Chan, M.F. Brady, R.T. Penson, H. Huang, M.J. Birrer, J.L. Walker, et al., Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N. Engl. J. Med.. 374 (8) (2016) 738–48.

      15. C.S. Ng, Z Zhang, S.I. Lee, H.S. Marques, K. Burgers, F. Su, et al., CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: an ACRIN and GOG study. Clin. Cancer Res.. 23 (14) (2017) 3684–3691.

      16. M.E. van der Burg, M. van Lent, M. Buyse, A. Kobierska, N. Colombo, G. Favalli, et al., The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecologic cancer cooperative group of the European organization for research and treatment of cancer. N. Engl. J. Med.. 332 (10) (1995) 629–34.

      17. P.G. Rose, S. Nerenstone, M.F. Brady, D. Clarke-Pearson, G. Olt, S.C. Rubin, et al., Secondary surgical cytoreduction for advanced ovarian carcinoma. N. Engl. J. Med.. 351 (24) (2004) 2489–2497.

      18. D.S. Alberts, P.Y. Liu, E.V. Hannigan, R. O'Toole, S.D. Willliams, J.A. Young, et al., Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med.. 335 (1996) 1950–1955.

      19. M. Markman, B.N. Bundy, D.S. Alberts, J.M. Fowler, D.L. Clark-Pearson, L.F. Carson, et al., Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the gynecologic oncology group, southwestern oncology group, and eastern cooperative oncology group. J. Clin. Oncol.. 19 (4) (2001) 1001–7.

      20. D.K. Armstrong, B. Bundy, L. Wenzel, H.Q. Huang, R. Baergen, S. Lele, et al., Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med.. 354 (1) (2006) 34–43.

      21. J.L. Walker, M.F. Brady, P.A. DiSilvestro, K Fujiwara, D. Alberts, W. Zheng, et al., A phase III clinical trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube and primary peritoneal carcinoma NCI-supplied agent (s): Bevacizumab (NSC #704865 IND #7921) NCT01167712 a GOG/NRG trial (GOG 252). Society of Gynecologic Oncology Annual Meeting, San Diego, CA, March, 2016.

      22. M. Markman, P. Liu, S. Wilczynski, et al., Phase III randomized trial of 12 months VS 3 months of paclitaxel in patients with advanced ovarian, fallopian tube or primary peritoneal cancer who attain a clinically defined complete response (CR) following platinum/paclitaxel-based chemotherapy. J. Clin. Oncol.. 21(13) (2003) 2460–2465.

      23. L.J. Copeland, M.F. Brady, R.A. Burger, W.H. Rodgers, H. Huang, D. Cella, et al., A phase III trial of maintenance therapy in women with advanced ovarian/fallopian tube/peritoneal cancer (O/PC/FT) after a complete clinical response (CCR) to first-line therapy – an nrg oncology study. Presented at the Society of Gynecologic Annual Meeting, National Harbor, MD, March, 2017.

      24. V.E. von Gruenigen, H.Q. Huang, J.H Beumer, H.A. Lankes, W. Tew, T. Herzog, et al., Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer-an NRG oncology/gynecologic oncology group study. Gynecol. Oncol. 144 (3) (2017) 459–67.

      25. R.L. Coleman, D. Enserro, N. Spirtos, T.J. Herzog, P. Sabbatini, D. Kay, et al., A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): a NRG oncology/gynecologic oncology group(GOG) study. Abstract Presented at American Society of Clinical Oncology Annual Meeting, Chicago, IL 2018

        • Burger R.A.
        • Sill M.W.
        • Monk B.J.
        • Greer B.E.
        • Sorosky J.I.
        Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study.
        J. Clin. Oncol. 2007; 25: 5165-5171
      26. R.L. Coleman, M.F. Brady, T.J. Herzog, P. Sabbatini, D.K. Armstrong, J.L. Walker, et al., Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian (NRG oncology/gynecologic oncology group study GOG-0213): a multicenter, open-label, randomized, phase 3 trial. Lancet Oncol. 18 (6) (2017) 779–91.

      27. B.J. Monk, M.W. Sill, J.L. Walker, C.J. Darus, G. Sutton, K.S. Tewari, et al., Randomized phase II evaluation of bevacizumab versus bevacizumab plus Fosbretabulin in recurrent ovarian, tubal, or peritoneal carcinoma: an NRG oncology/gynecologic oncology group study. J. Clin. Oncol.. 34 (19) (2016) 2279–86.

      28. Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients with Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer. n.d. (Clinical identifier NCT009989651).

      29. R.L. Coleman, M.W. Sill, K. Bell-McGuinn, C Aghajanian, H.J. Gray, K.S. Tewari, et al., A phase II evaluation of the potent, highly selective PARP inhibitor, veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation-an NRG oncology/gynecologic oncology group study. Gynecol. Oncol.. 137 (3) (2015) 386–391.

      30. J.F. Liu, W.T. Barry, M Birrer, J.M. Lee, R.J. Buckanovich, G.F. Fleming, et al., Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitibe ovarian cancer: a randomized phase 2 study. Lancet Oncol. 15 (11) (2014) 1207–14.

      31. R.A. Burger, M. Sill, D. Zamarin, D. Powell, I. Frak, O. Zivanovic, et al., Phase II randomized trial of nivolumab with or without ipilimumab in patients with persistent or recurrent ovarian cancer (NRG GY003). International Gynecologic Cancer Society 17th Biennial Meeting, Kyoto, Japan, September, 2018.

        • Konstantinopoulos P.A.
        • Brady W.E.
        • Farley J.
        • Armstrong A.
        • Uyar D.S.
        • Gershenson D.M.
        Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG_GY001).
        Gynecol. Oncol. 2018; 150: 9-13
      32. B.J. Monk, M.W. Sill, P Hanjani, R. Edwards, J. Rotmensch, K. De Geest, et al., Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the gynecologic oncology group. Gynecol. Oncol.. 120 (3) (2011) 459–63.

      33. W.P. Tew, M.W. Sill, J.L. Walker, A.A. Secord, A.J. Bonebrake, J.M. Schilder, et al., Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: an NRG oncology/gynecologic oncology group study. Gynecol. Oncol. 151 (2) (2018) 257–63

      34. M.A. Morgan, M.W. Sill, K. Fujiwara, B. Greer, S.C. Rubin, K DeGeest, et al., A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol. Oncol. 121 (2) (2011) 264–8.

        • Look K.Y.
        • Bookman M.A.
        • Schol J.
        • Herzog T.J.
        • Rocereto T.
        • Vinters J.
        Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a gynecologic oncology group study.
        Gynecol. Oncol. 2004; 92: 93-100
      35. B.J. Monk, W.E. Brady, H.A. Lankes, A. Facciabene, K. Manjarez, R.B. Hershberg, et al., VTX-2337, a TLR8 agonist, plus chemotherapy in recurrent ovarian cancer: preclinical and phase I data by the gynecologic oncology group. J Clin Onc 31 (15s) (2013) 1925.

      36. P.H. Thaker, W.E. Brady, H.A. Lankes, K. Odunsi W.H. Bradley, K.N. Moore, et al., A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: an NRG oncology/gynecologic oncology group study. Gynecol. Oncol. 147 (2) (2017) 283–90.

      37. D.A. Jandiial, W.E. Brady, S.B. Howell, H.A. Lankes, R.J. Schilder, J.H. Beumer, et al., A phase I pharnocokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: an NRG oncology/gynecologic oncology group study. Gynecol. Oncol. 145 (2) (2017) 236–42.